Ionis Pharmaceuticals’ (IONS) Hold Rating Reiterated at Cowen and Company

Cowen and Company reiterated their hold rating on shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) in a report published on Friday morning.

“Ionis provided an update on its pipeline of ~40 antisense drug candidates.”,” the firm’s analyst commented.

Several other brokerages have also weighed in on IONS. Piper Jaffray Companies reissued an overweight rating and issued a $46.00 price objective on shares of Ionis Pharmaceuticals in a research report on Monday, September 26th. BMO Capital Markets increased their price objective on shares of Ionis Pharmaceuticals from $61.00 to $68.00 and gave the company an outperform rating in a research report on Wednesday, December 28th. Laidlaw increased their price objective on shares of Ionis Pharmaceuticals from $59.00 to $65.00 and gave the company a buy rating in a research report on Tuesday, December 27th. Zacks Investment Research raised shares of Ionis Pharmaceuticals from a hold rating to a buy rating and set a $51.00 price objective on the stock in a research report on Wednesday, November 16th. Finally, Janney Montgomery Scott started coverage on shares of Ionis Pharmaceuticals in a research report on Wednesday, September 28th. They issued a buy rating and a $47.00 price objective on the stock. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus target price of $46.48.

Analyst Recommendations for Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis Pharmaceuticals (NASDAQ:IONS) traded down 3.5352% during trading on Friday, reaching $48.2999. 1,923,634 shares of the company’s stock were exchanged. Ionis Pharmaceuticals has a 52-week low of $19.59 and a 52-week high of $59.04. The firm’s market cap is $5.85 billion. The stock’s 50 day moving average price is $47.52 and its 200 day moving average price is $35.01.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings data on Wednesday, November 9th. The company reported $0.06 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.08 by $0.02. The company earned $110.90 million during the quarter, compared to the consensus estimate of $114.65 million. Ionis Pharmaceuticals had a negative net margin of 77.30% and a negative return on equity of 120.60%. Ionis Pharmaceuticals’s revenue was up 125.9% compared to the same quarter last year. Equities research analysts anticipate that Ionis Pharmaceuticals will post ($1.05) EPS for the current fiscal year.

WARNING: This story was first posted by BBNS and is the sole property of of BBNS. If you are reading this story on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright law. The correct version of this story can be accessed at https://baseballnewssource.com/markets/ionis-pharmaceuticals-ions-hold-rating-reiterated-at-cowen-and-company/344845.html.

In other Ionis Pharmaceuticals news, COO B Lynne Parshall sold 4,000 shares of the firm’s stock in a transaction dated Thursday, December 15th. The shares were sold at an average price of $50.00, for a total value of $200,000.00. Following the transaction, the chief operating officer now directly owns 16,693 shares of the company’s stock, valued at approximately $834,650. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP C Frank Bennett sold 5,000 shares of the firm’s stock in a transaction dated Monday, November 7th. The shares were sold at an average price of $34.00, for a total transaction of $170,000.00. Following the completion of the transaction, the senior vice president now directly owns 15,803 shares in the company, valued at $537,302. The disclosure for this sale can be found here. 1.86% of the stock is currently owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in IONS. BlackRock Fund Advisors increased its stake in Ionis Pharmaceuticals by 2.8% in the third quarter. BlackRock Fund Advisors now owns 2,878,111 shares of the company’s stock worth $105,454,000 after buying an additional 77,715 shares during the last quarter. IronBridge Capital Management LP increased its stake in Ionis Pharmaceuticals by 10.5% in the third quarter. IronBridge Capital Management LP now owns 93,890 shares of the company’s stock worth $3,440,000 after buying an additional 8,915 shares during the last quarter. Tocqueville Asset Management L.P. increased its stake in Ionis Pharmaceuticals by 21.9% in the second quarter. Tocqueville Asset Management L.P. now owns 1,326,120 shares of the company’s stock worth $30,885,000 after buying an additional 238,566 shares during the last quarter. TIAA CREF Investment Management LLC increased its stake in Ionis Pharmaceuticals by 5.7% in the third quarter. TIAA CREF Investment Management LLC now owns 383,160 shares of the company’s stock worth $14,039,000 after buying an additional 20,521 shares during the last quarter. Finally, Neuberger Berman Group LLC increased its stake in Ionis Pharmaceuticals by 23.8% in the second quarter. Neuberger Berman Group LLC now owns 20,516 shares of the company’s stock worth $478,000 after buying an additional 3,948 shares during the last quarter. 87.72% of the stock is currently owned by hedge funds and other institutional investors.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc, formerly Isis Pharmaceuticals, Inc, is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Company operates through two segments: Ionis Core and Akcea Therapeutics. The Company’s Ionis Core segment is developing a drug discovery platform.

5 Day Chart for NASDAQ:IONS

Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 

Latest News

Orioles Talking Contract with Slugger Jose Bautista
Orioles Talking Contract with Slugger Jose Bautista
Criticism During World Series Humorous to Joe Maddon
Criticism During World Series Humorous to Joe Maddon
Los Angeles Dodgers Awaiting Decision by Twins on Brian Dozier
Los Angeles Dodgers Awaiting Decision by Twins on Brian Dozier
Manny Ramirez Returning to Play Baseball in Japan
Manny Ramirez Returning to Play Baseball in Japan
Rajai Davis Anxious to Start Second Stint With Oakland
Rajai Davis Anxious to Start Second Stint With Oakland
Offseason Moves, Rumors and Possible Deals
Offseason Moves, Rumors and Possible Deals


Leave a Reply

 
© 2006-2017 BBNS.